| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 422.82% | £365,972.36 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 377.83% | £334,481.54 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 266.96% | £256,872.33 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 56.24% | £109,368.78 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 45.01% | £101,508.32 |
| Lord Mance |
|
Stryker / NYQ:SYK | 31.98% | £92,384.73 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | 10.94% | £77,661.28 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 9.56% | £76,688.71 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -0.48% | £69,666.57 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -37.92% | £43,457.53 |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -53.47% | £32,567.98 | |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |